Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) after Frontline Therapy with Hyper-CVAD Regimens.

被引：0
|
作者：
Thomas, Deborah A.
O'Brien, Susan [1 ]
Rytting, Michael
Faderl, Stefan
Cortes, Jorge
Wierda, William G.
Ravandi, Farhad [1 ]
Kantarjian, Hagop M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：674 / 674
页数：1
相关论文
共 50 条
  • [21] FEASIBILITY OF HYPER-CVAD IN ADOLESCENTS AND ADULTS PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    Portugal, R.
    Pulcheri, W.
    Loureiro, M.
    Nucci, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 492 - 492
  • [22] Frontline Ofatumumab with Hyper-CVAD in CD20+Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    Ravandi, Farhad
    Thomas, Deborah
    Khouri, Maria
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Cortes, Jorge
    Short, Nicholas
    Sasaki, Koji
    Issa, Ghayas
    Koller, Paul
    Schroeder, Heather
    Kadia, Tapan
    Verstovsek, Srdan
    Daver, Naval
    Jain, Nitin
    Konopleva, Marina
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S256 - S257
  • [23] Clinical outcome of the treatment of adult acute lymphoblastic leukemia (ALL) with the hyper-CVAD protocol.
    Marinakis, T
    Zomas, A
    Galanopoulos, AG
    Michalis, E
    Gortzolidis, G
    Tsourveloudis, L
    Savvidou, L
    Theodoropoulos, G
    Papadhimitriou, S
    Paterakis, G
    Grigoraki, V
    Georgiakaki, M
    Anagnostopoulos, NI
    BLOOD, 2005, 106 (11) : 226B - 226B
  • [24] Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
    Jabbour, Elias
    Hagop, Kantarjian
    Thomas, Deborah
    Garcia-Manero, Guillermo
    Hoehn, Daniela
    Garris, Rebecca
    Faderl, Stefan H.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Ravandi, Farhad
    Verstovsek, Srdan
    O'Brien, Susan
    BLOOD, 2013, 122 (21)
  • [25] A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+acute lymphoblastic leukemia (ALL): Updated results.
    Bazarbachi, Abdul Hamid
    Yilmaz, Musa
    Ravandi, Farhad
    Thomas, Deborah A.
    Khouri, Maria
    Garcia-Manero, Guillermo
    Garris, Rebecca S.
    Cortes, Jorge E.
    Short, Nicholas James
    Sasaki, Koji
    Issa, Ghayas C.
    Koller, Paul B.
    Kadia, Tapan M.
    Verstovsek, Srdan
    Daver, Naval Guastad
    Jain, Nitin
    Konopleva, Marina
    O'Brien, Susan Mary
    Jabbour, Elias
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL)
    Thomas, D. A.
    Kantarjian, H. M.
    Cortes, J. E.
    Ravandi, F.
    Faderl, S.
    Jones, D.
    Letvak, L.
    Champlin, R. E.
    O'Brien, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab As Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Sasaki, Koji
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Cortes, Jorge E.
    Kadia, Tapan M.
    Ravandi, Farhad
    Verstovsek, Srdan
    O'Brien, Susan
    BLOOD, 2014, 124 (21)
  • [28] Feasibility and Outcome of the Hyper-CVAD Regimen in Patients With Adult Acute Lymphoblastic Leukemia
    Portugal, Rodrigo Doyle
    Loureiro, Monique M.
    Garnica, Marcia
    Pulcheri, Wolmar
    Nucci, Marcio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (01): : 52 - 57
  • [29] The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
    Jain, P.
    Kantarjian, H.
    Ravandi, F.
    Thomas, D.
    O'Brien, S.
    Kadia, T.
    Burger, J.
    Borthakur, G.
    Daver, N.
    Jabbour, E.
    Konopleva, M.
    Cortes, J.
    Pemmaraju, N.
    Kelly, M. A.
    Cardenas-Turanzas, M.
    Garris, R.
    Faderl, S.
    LEUKEMIA, 2014, 28 (04) : 973 - 975
  • [30] The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
    P Jain
    H Kantarjian
    F Ravandi
    D Thomas
    S O'Brien
    T Kadia
    J Burger
    G Borthakur
    N Daver
    E Jabbour
    M Konopleva
    J Cortes
    N Pemmaraju
    M A Kelly
    M Cardenas-Turanzas
    R Garris
    S Faderl
    Leukemia, 2014, 28 : 973 - 975
12345